Home » Authors » Brady Huggett

Articles by Brady Huggett

Cypress Bioscience Raises $10.3M For Milnacipran Phase III Program

March 28, 2003

By Brady Huggett

Cypress Bioscience Raises $10.3M For Milnacipran Phase III Program

March 28, 2003

By Brady Huggett

Alteon Raises $7.7M Privately For ALT-711, Other Products

March 27, 2003

By Brady Huggett

Merck Accepts Kalypsys Invite, Ends Up Signing Platform Deal

March 27, 2003

By Brady Huggett

Merck Accepts Kalypsys Invite, Ends Up Signing Platform Deal

March 27, 2003

By Brady Huggett

Alteon Raises $7.7M Privately For ALT-711, Other Products

March 27, 2003

By Brady Huggett

Biopure Plans To Raise $13.4M While Awaiting Word From FDA

March 26, 2003

By Brady Huggett

Biopure Plans To Raise $13.4M While Awaiting Word From FDA

March 26, 2003

By Brady Huggett

Dermatology Meeting Brings Together Psoriasis Competitors

March 25, 2003

By Brady Huggett

Dermatology Meeting Brings Together Psoriasis Competitors

March 25, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 3, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 3, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Radiopharma Telix acquires FAP-targeting agents for bladder cancer
BioWorld
Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.